TrialAnnals of oncology : official journal of the European Society for Medical Oncology2016

Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer.

L Paz-Ares et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.